Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ruiz, J.
Right arrow Articles by Vila, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruiz, J.
Right arrow Articles by Vila, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2001) 48, 545-548
© 2001 The British Society for Antimicrobial Chemotherapy

Brief report

Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones

Joaquim Ruiza, Angels Juradoa, Elena Garcia-Méndezb, Francesc Marcoa, Lorenzo Aguilarb, M. T. Jiménez de Antaa and Jordi Vilaa,*

a Institut Clínic d'Infeccions i Immunologia, IDIBAPS, Hospital Clínic, Villarroel 170, 08036 Barcelona; b GlaxoSmithKline, Madrid, Spain

We studied the frequency of mutation of clinical isolates of Neisseria gonorrhoeae (two nalidixic acid susceptible and two nalidixic acid resistant), and the stability of the mutants obtained, in the presence of three different concentrations of five fluoroquinolones. The frequency of mutation was low for all the quinolones. Only one N. gonorrhoeae mutant, obtained with trovafloxacin at 4 x MIC presented a stable increase in the MIC of this quinolone, not attributable to novel mutation(s), both in the gyrA and parC genes, although not showing any increase in the MIC of the other quinolones tested. In summary, gemifloxacin was the only quinolone tested for which resistant mutants were not obtained.

* Corresponding author. Tel: +34-93-227-5522; Fax: +34-93-227-5454; E-mail: vila{at}medicina.ub.es


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
G. P. Allen and C. D. Hankins
Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae
J. Antimicrob. Chemother., August 1, 2009; 64(2): 359 - 363.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Ruiz, L. Mensa, M. J. Pons, J. Vila, and J. Gascon
Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1016 - 1019.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.